Section 232 Pharmaceutical Tariffs: Preparing the September 29

September 29, 2026 brings the next implementation date under the U.S. Section 232 pharmaceutical program. For importers of covered patented pharmaceuticals and associated ingredients, the customs review needs to connect product details with the applicable company and tariff treatment.

Proclamation 11020 established July 31 as the start date for products of companies listed in Annex III and September 29 for products of other companies. CBP’s implementation guidance follows that distinction.

The practical result is an entry-specific analysis. A broad description such as pharmaceutical ingredient does not provide enough information to select the rate or the reporting provision.

Understand what the 100% rate covers

The proclamation prescribes a 100% rate for covered patented pharmaceuticals and associated ingredients, subject to alternative treatments within the program. Its calculation rule generally combines the applicable Column 1 duty with the pharmaceutical Section 232 duty to reach the prescribed rate, with stated exceptions.

That is why importers should not automatically add 100 percentage points to every existing duty calculation. The product’s applicable treatment must be established first. Other independently applicable duties and charges also require review; the combined-rate rule should not be read as a universal cap on all import costs.

Finance teams should show the calculation clearly enough that the broker and internal reviewer can trace each component to its supporting provision.

Confirm product status and scope

The program distinguishes patented pharmaceuticals from generic pharmaceuticals and their associated ingredients. Generics are not subject to these pharmaceutical Section 232 duties at this time. The importer still needs a supported product record. Confirm the underlying HTSUS classification, the product’s status, its relationship to any pharmaceutical ingredient provision and the information needed to assess the scope of the applicable tariff note.

Supplier descriptions should be specific enough to support that review. Where technical or regulatory information is missing, obtain it before the entry deadline. A familiar product name or an internal stock code cannot replace the facts needed for customs reporting.

Evaluate alternative treatment with evidence

The proclamation provides alternative treatment linked to specified origins, qualifying company arrangements and certain product categories. It also establishes that the lowest applicable rate within the proclamation applies when a product qualifies for more than one of its rates.

Eligibility needs support. Identify the relevant manufacturer or company, the origin of the imported article and the current official requirements for the treatment being claimed. Review the applicable annexes and any subsequent implementation notices.

A manufacturer’s investment announcement or a supplier’s statement that its products are exempt should trigger a documentation request. The entry file needs the basis for the actual claim and confirmation that it applies to the merchandise being imported.

Apply the correct date trigger

For the companies subject to the later start date, the pharmaceutical duties apply to goods entered for consumption or withdrawn from warehouse for consumption at or after 12:01 a.m. Eastern Time on September 29.

Departure from the supplier before that date does not establish earlier treatment. Review the expected entry or withdrawal event, along with any other applicable instructions, when assessing shipments already moving.

For bonded inventory, coordinate the planned withdrawal with the broker and warehouse team. Procurement, finance and operations should use the same date assumptions so the cost model matches the entry being prepared.

Chapter 99 reporting remains part of the review

CBP’s guidance requires an applicable Chapter 99 classification for imports falling within the designated Chapter 29 and Chapter 30 provisions. This reporting requirement can remain relevant even when the applicable pharmaceutical Section 232 additional duty is zero.

The review therefore needs two connected classifications: the underlying HTSUS provision and the Chapter 99 provision supporting the claimed treatment. Validate the combination against the current tariff schedule and CBP instructions.

Trade agreement eligibility also needs a separate check. CBP states that the pharmaceutical Section 232 headings can apply in addition to preferential treatment under covered trade agreements. Canadian origin or USMCA eligibility alone should not be treated as a complete answer to Section 232 exposure.

Review FTZ and drawback implications separately

The proclamation and CBP guidance contain privileged-foreign-status requirements for covered merchandise subject to the duties and admitted into a U.S. FTZ on or after the applicable effective date, subject to the stated domestic-status exception.

FTZ users should connect the product determination with admission status and the planned entry for consumption. Zone operations need the same validated product information used by the customs entry team.

The pharmaceutical action also makes drawback available for its duties. That creates a reason to examine qualifying export activity and supporting records, but it does not establish that every importer or transaction qualifies for a refund. A separate eligibility and documentation review is needed.

Prepare one complete entry record

TradeFlex recommends bringing classification, product status, origin, manufacturer identity, company eligibility, relevant dates and Chapter 99 reporting into one review. Identify missing information and assign responsibility for obtaining it before filing.

That record should support both the customs entry and the landed-cost model. It gives finance a defensible calculation and gives operations clearer instructions for the shipment.

TradeFlex can help review Section 232 treatment, customs reporting, FTZ considerations and potential drawback opportunities. Contact our team to assess the information needed for your next pharmaceutical entry.